MINNEAPOLIS - FOXO Technologies Inc. (NYSE American: FOXO), a biotechnology firm, announced today a non-binding agreement for a proposed merger with M2i Global, Inc. (OTC: MTWO), a company focused on developing a global value supply chain for critical minerals. The merger aims to combine FOXO's artificial intelligence capabilities with M2i's expertise in securing mineral reserves for the U.S. government and free trade partners.
M2i Global specializes in creating strategic mineral reserves in partnership with the U.S. Federal Government and is recognized for its role in ensuring a stable supply of critical materials for national defense and economic security. The company's mission includes building a comprehensive supply chain for these minerals, collaborating with government, industry, non-profits, and academia.
Interim CEO of FOXO Technologies, Mark White, expressed enthusiasm about the merger. He highlighted the experience and track record of M2i's management team, including Executive Chairman Doug Cole, who is known for his role in the turnaround of American Battery Metals Corporation. White anticipates that the artificial intelligence developed by FOXO will accelerate M2i's growth strategy and enhance operational efficiency.
FOXO Technologies brings to the merger its expertise in epigenetic technology, applying AI to analyze DNA methylation patterns to identify biomarkers of human health and aging. The company has been dedicated to improving human health and longevity, with a focus on life insurance industries.
The press release also contained forward-looking statements, cautioning that actual events could differ materially from those anticipated due to various risks and uncertainties. Factors that could influence the outcome include regulatory changes, competitive industries, and the ability to implement business plans and obtain financing.
This announcement is based on a press release statement and does not constitute an endorsement of the merger's potential success or the companies involved. The merger remains subject to customary closing conditions and regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.